Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLoans - Loss AllowanceLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Receivables - Accured (2020 - 2025)

Historic Revenue - Other for Innate Pharma (IPHA) over the last 4 years, with Q4 2024 value amounting to $21.5 million.

  • Innate Pharma's Revenue - Other fell 6758.06% to $21.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $199.3 million, marking a year-over-year change of. This contributed to the annual value of $11905.7 for FY2024, which is 5.74% up from last year.
  • As of Q4 2024, Innate Pharma's Revenue - Other stood at $21.5 million, which was down 6758.06% from $66.3 million recorded in Q4 2023.
  • Over the past 5 years, Innate Pharma's Revenue - Other peaked at $83.2 million during Q4 2020, and registered a low of $21.5 million during Q4 2024.
  • Its 5-year average for Receivables - Accured is $194864.9, with a median of $204726.2 in 2021.
  • Its Receivables - Accured has fluctuated over the past 5 years, first soared by 14373.36% in 2021, then plummeted by 2286.97% in 2023.
  • Over the past 4 years, Innate Pharma's Revenue - Other (Quarter) stood at $83.2 million in 2020, then crashed by 66.03% to $28.3 million in 2021, then surged by 134.69% to $66.3 million in 2023, then tumbled by 67.58% to $21.5 million in 2024.
  • Its Revenue - Other was $21.5 million in Q4 2024, compared to $66.3 million in Q4 2023 and $28.3 million in Q4 2021.